Literature DB >> 24825341

Advanced glycation/glycoxidation endproduct carboxymethyl-lysine and incidence of coronary heart disease and stroke in older adults.

Jorge R Kizer1, David Benkeser2, Alice M Arnold2, Joachim H Ix3, Kenneth J Mukamal4, Luc Djousse5, Russell P Tracy6, David S Siscovick7, Bruce M Psaty8, Susan J Zieman9.   

Abstract

BACKGROUND: Advanced glycation/glycoxidation endproducts (AGEs) accumulate in settings of increased oxidative stress--such as diabetes, chronic kidney disease and aging--where they promote vascular stiffness and atherogenesis, but the prospective association between AGEs and cardiovascular events in elders has not been previously examined.
METHODS: To test the hypothesis that circulating levels of N(ɛ)-carboxymethyl-lysine (CML), a major AGE, increase the risk of incident coronary heart disease and stroke in older adults, we measured serum CML by immunoassay in 2111 individuals free of prevalent cardiovascular disease participating in a population-based study of U.S. adults ages 65 and older.
RESULTS: During median follow-up of 9.1 years, 625 cardiovascular events occurred. CML was positively associated with incident cardiovascular events after adjustment for age, sex, race, systolic blood pressure, anti-hypertensive treatment, diabetes, smoking status, triglycerides, albumin, and self-reported health status (hazard ratio [HR] per SD [0.99 pmol/l] increase=1.11, 95% confidence interval [CI]=1.03-1.19). This association was not materially attenuated by additional adjustment for C-reactive protein, estimated glomerular filtration rate (eGFR), and urine albumin/creatinine ratio. Findings were similar for the component endpoints of coronary heart disease and stroke.
CONCLUSIONS: In this large older cohort, CML was associated with an increased risk of cardiovascular events independent of a wide array of potential confounders and mediators. Although the moderate association limits CML's value for risk prediction, these community-based findings provide support for clinical trials to test AGE-lowering therapies for cardiovascular prevention in this population.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Advanced glycation endproducts; Aging; Carboxymethyl-lysine; Coronary heart disease; Older adults; Stroke

Mesh:

Substances:

Year:  2014        PMID: 24825341      PMCID: PMC4169874          DOI: 10.1016/j.atherosclerosis.2014.04.013

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  43 in total

Review 1.  Does accumulation of advanced glycation end products contribute to the aging phenotype?

Authors:  Richard D Semba; Emily J Nicklett; Luigi Ferrucci
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-05-17       Impact factor: 6.053

Review 2.  AGE restriction in diabetes mellitus: a paradigm shift.

Authors:  Helen Vlassara; Gary E Striker
Journal:  Nat Rev Endocrinol       Date:  2011-05-24       Impact factor: 43.330

3.  Measures of adiposity and future risk of ischemic stroke and coronary heart disease in older men and women.

Authors:  Jorge R Kizer; Mary L Biggs; Joachim H Ix; Kenneth J Mukamal; Susan J Zieman; Ian H de Boer; Dariush Mozaffarian; Joshua I Barzilay; Elsa S Strotmeyer; Jose A Luchsinger; Mitchell S V Elkind; W T Longstreth; Lewis H Kuller; David S Siscovick
Journal:  Am J Epidemiol       Date:  2010-12-01       Impact factor: 4.897

4.  Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults.

Authors:  Elizabeth Selvin; Michael W Steffes; Hong Zhu; Kunihiro Matsushita; Lynne Wagenknecht; James Pankow; Josef Coresh; Frederick L Brancati
Journal:  N Engl J Med       Date:  2010-03-04       Impact factor: 91.245

5.  Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease.

Authors:  Helen Vlassara; Jaime Uribarri; Weijing Cai; Susan Goodman; Renata Pyzik; James Post; Fabrizio Grosjean; Mark Woodward; Gary E Striker
Journal:  Clin J Am Soc Nephrol       Date:  2012-03-29       Impact factor: 8.237

6.  Fat mass is inversely associated with serum carboxymethyl-lysine, an advanced glycation end product, in adults.

Authors:  Richard D Semba; Lenore Arab; Kai Sun; Emily J Nicklett; Luigi Ferrucci
Journal:  J Nutr       Date:  2011-07-20       Impact factor: 4.798

7.  Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects.

Authors:  Jaime Uribarri; Alin Stirban; Denise Sander; Weijing Cai; Monica Negrean; Cristina E Buenting; Theodore Koschinsky; Helen Vlassara
Journal:  Diabetes Care       Date:  2007-05-11       Impact factor: 19.112

8.  Plasma carboxymethyl-lysine, an advanced glycation end product, and all-cause and cardiovascular disease mortality in older community-dwelling adults.

Authors:  Richard D Semba; Stefania Bandinelli; Kai Sun; Jack M Guralnik; Luigi Ferrucci
Journal:  J Am Geriatr Soc       Date:  2009-08-13       Impact factor: 5.562

9.  Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.

Authors:  Johanna W Nin; Anders Jorsal; Isabel Ferreira; Casper G Schalkwijk; Martin H Prins; Hans-Henrik Parving; Lise Tarnow; Peter Rossing; Coen D Stehouwer
Journal:  Diabetes Care       Date:  2011-02       Impact factor: 19.112

10.  Early progression of diabetic nephropathy correlates with methylglyoxal-derived advanced glycation end products.

Authors:  Paul J Beisswenger; Scott K Howell; Gregory B Russell; Michael E Miller; Stephen S Rich; Michael Mauer
Journal:  Diabetes Care       Date:  2013-06-18       Impact factor: 19.112

View more
  26 in total

1.  A prospective study of soluble receptor for advanced glycation end-products and colorectal cancer risk in postmenopausal women.

Authors:  Liang Chen; Zhigang Duan; Lesley Tinker; Haleh Sangi-Haghpeykar; Howard Strickler; Gloria Y F Ho; Marc J Gunter; Thomas Rohan; Craig Logsdon; Donna L White; Kathryn Royse; Hashem B El-Serag; Li Jiao
Journal:  Cancer Epidemiol       Date:  2016-04-18       Impact factor: 2.984

2.  Diacetyl/l-Xylulose Reductase Mediates Chemical Redox Cycling in Lung Epithelial Cells.

Authors:  Shaojun Yang; Yi-Hua Jan; Vladimir Mishin; Diane E Heck; Debra L Laskin; Jeffrey D Laskin
Journal:  Chem Res Toxicol       Date:  2017-06-26       Impact factor: 3.739

3.  Cross-sectional Analysis of AGE-CML, sRAGE, and esRAGE with Diabetes and Cardiometabolic Risk Factors in a Community-Based Cohort.

Authors:  Stephanie J Loomis; Yuan Chen; David B Sacks; Eric S Christenson; Robert H Christenson; Casey M Rebholz; Elizabeth Selvin
Journal:  Clin Chem       Date:  2017-03-09       Impact factor: 8.327

4.  Carboxymethyl lysine, an advanced glycation end product, and incident diabetes: a case-cohort analysis of the ARIC Study.

Authors:  V C Luft; B B Duncan; M I Schmidt; L E Chambless; J S Pankow; R C Hoogeveen; D J Couper; G Heiss
Journal:  Diabet Med       Date:  2015-10-06       Impact factor: 4.359

5.  Sleep-disordered breathing is associated with higher carboxymethyllysine level in elderly women but not elderly men in the cardiovascular health study.

Authors:  Peter D Ahiawodzi; Richard A Kerber; Kira C Taylor; Frank D Groves; Elizabeth O'Brien; Joachim H Ix; Jorge R Kizer; Luc Djoussé; Russell P Tracy; Anne B Newman; David S Siscovick; John Robbins; Kenneth Mukamal
Journal:  Biomarkers       Date:  2017-01-25       Impact factor: 2.658

Review 6.  Therapeutic potential of vitamin D in AGE/RAGE-related cardiovascular diseases.

Authors:  Ting-Wei Lee; Yu-Hsun Kao; Yi-Jen Chen; Tze-Fan Chao; Ting-I Lee
Journal:  Cell Mol Life Sci       Date:  2019-06-27       Impact factor: 9.261

7.  Advanced glycation end product carboxymethyl-lysine and risk of incident peripheral artery disease in older adults: The Cardiovascular Health Study.

Authors:  Parveen K Garg; Mary L Biggs; Joshua Barzilay; Luc Djousse; Calvin Hirsch; Joachim H Ix; Jorge R Kizer; Russell P Tracy; Anne B Newman; David S Siscovick; Kenneth J Mukamal
Journal:  Diab Vasc Dis Res       Date:  2019-05-08       Impact factor: 3.291

8.  Advanced-Glycation End-Products Induce Podocyte Injury and Contribute to Proteinuria.

Authors:  Rajkishor Nishad; Vazeeha Tahaseen; Rajesh Kavvuri; Manga Motrapu; Ashish K Singh; Kiranmayi Peddi; Anil K Pasupulati
Journal:  Front Med (Lausanne)       Date:  2021-07-01

9.  Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes.

Authors:  Vincent M Monnier; Wanjie Sun; Xiaoyu Gao; David R Sell; Patricia A Cleary; John M Lachin; Saul Genuth
Journal:  Cardiovasc Diabetol       Date:  2015-09-05       Impact factor: 9.951

Review 10.  RAGE Expression and ROS Generation in Neurons: Differentiation versus Damage.

Authors:  S Piras; A L Furfaro; C Domenicotti; N Traverso; U M Marinari; M A Pronzato; M Nitti
Journal:  Oxid Med Cell Longev       Date:  2016-05-25       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.